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Abstract. Malaria rapid diagnostic tests (RDTs) may improve fever management in areas without microscopy. We
compared the accuracy of histidine-rich protein 2 (HRP2) and Plasmodium lactate dehydrogenase (pLDH)-based RDTs,
using expert microscopy as a gold standard, for initial diagnosis, treatment monitoring, and diagnosis of recurrent malaria
in a cohort of children followed longitudinally in a high-transmission area in Uganda. For 305 initial fever episodes,
sensitivity was 98% for HRP2 and 87% for pLDH, whereas specificity was 55% and 96%, respectively. The HRP2 gave
51% false-positive results on Day 28, whereas pLDH gave no false positives after Day 7. For 59 recurrent fever episodes
during follow-up, sensitivity was 100% for HRP2 and 91% for pLDH, whereas specificity was 33% and 100%, respec-
tively. The HRP2-based RDTs are useful for initial diagnosis of malaria caused by superior sensitivity; however, as
a result of superior specificity, pLDH-based RDTs are more appropriate to monitor treatment and diagnose recur-
rent malaria.
INTRODUCTION
Uganda has some of the highest malaria transmission inten-
sities reported in the world.1 High malaria transmission areas
are characterized by a high prevalence of parasitemia in the
population and frequent malaria episodes, especially in chil-
dren < 5 years of age. Parasitological diagnosis using either
microcopy or malaria rapid diagnostic tests is recommended
before antimalarial treatment.2 Despite this recommendation,
clinical diagnosis of malaria is still practiced in many areas
leading to significant over-diagnosis caused by symptom over-
lap with other causes of fever, indiscriminate use of anti-
malarials, and failure to diagnose and treat alternative causes
of fever.3–5 Over-diagnosis of malaria and indiscriminate treat-
ment with artemisinin-based combination therapy (ACT)
leaves patients without correct diagnosis and treatment, may
result in increased pressure toward resistant parasites, leads to
significant wastage, and is costly and unsustainable. Malaria
rapid diagnostic tests (RDTs), which detect parasite antigen in
blood, are increasingly favored for diagnostic confirmation
because of their simplicity, low infrastructure requirements,
and rapid results.6 The most popular RDTs currently in use
identify histidine-rich protein 2 (HRP2) and/or Plasmodium
lactate dehydrogenase (pLDH). The HRP2-based RDTs have
been recommended for Uganda by the Ministry of Health on
the basis of accuracy and ease of use.7,8 Currently, HRP2 assays
appear to be somewhat more sensitive than pLDH-based
tests.8,9 However, HRP2 antigen remains in the bloodstream
for several weeks after parasite clearance, thus contributing
to false-positive results and limiting specificity.10–14 The
pLDH-based assays may be more useful for monitoring
patients’ recovery after treatment and avoiding unnecessary
retreatment of malaria because they turn negative soon after
parasite clearance from the blood.15 Additional information
on RDT performance in high transmission areas will be help-
ful in guiding policy and practice. We compared the perfor-
mance of one HRP2- and one pLDH-based RDT with expert
microscopy, in a cohort of children in a high transmission area
to 1) determine RDT accuracy for initial diagnosis of uncom-
plicated malaria, 2) compare duration of persistent anti-
genemia of HRP2 and pLDH after efficacious treatment of
uncomplicated malaria, and 3) determine RDT accuracy for
malaria diagnosis in patients returning with fever after effica-
cious treatment of uncomplicated malaria.
MATERIALS ANDMETHODS
Study site. The study was conducted in Tororo District
Hospital in eastern Uganda, a malaria hyperendemic area
between November 4, 2011 and January 14, 2012. The entomo-
logical inoculation rate in this area was estimated at 562 infec-
tive bites per person per year in 2002,1 and more recent reports
indicate persistent very high incidence of malaria in childhood
despite use of long-lasting insecticide-treated nets and ACT.16
The study was carried out alongside the Tororo Child Cohort
(TCC), a longitudinal antimalarial drug efficacy trial that
began in 2007. The primary objectives of the TCC were to
compare the incidence of malaria in a cohort of children strat-
ified by human immunodeficiency virus (HIV) status, mother’s
HIV status, and use of trimethoprim-sulfamethoxazole (TMP/
SMX) prophylaxis in an area where malaria is highly endemic;
to compare the efficacy, safety, and tolerability of artemether-
lumefantrine (AL) and dihydroartemisinin-piperaquine (DP)
for the treatment of uncomplicated falciparum malaria among
HIV-infected and uninfected children; and to assess the effect
of TMP-SMX prophylaxis on the incidence of malaria after
cessation of prophylaxis. Details of the screening and recruit-
ment of this cohort have been published previously.17 Briefly,
children were recruited from the antenatal and pediatric clinics
of Tororo Hospital and Tororo branch of The AIDS Support
Organization (TASO) if they fulfilled all of the following eligi-
bility criteria: 1) age 6 weeks to 12 months, 2) documentedHIV
status of mother and child, 3) agreement to come to the study
clinic for any febrile episode or other illness, 4) agreement
to avoid medications administered outside the study protocol,
5) willingness of parents or guardians to provide informed
consent, and 6) residence within 30 km radius of the study
clinic. Children in the study cohort were seen at least monthly
at the study clinic and encouraged to attend the clinic in case of
any illness and to avoid any medication not given at the study
*Address correspondence to Phoebe Mbabazi, International Hospi-
tal Kampala, P.O. Box 8177 Kampala, Uganda. E-mail: phibsmm@
gmail.com
530
clinic. At the beginning of the trial, participants were random-
ized to always receive either DP or AL in case of microscopy
confirmed malaria. Children who presented to the study clinic
with fever (tympanic temperature ³ 38°C and/or history of
fever in the previous 24 hours) and had a positive blood smear
were treated with antimalarials and followed up for 28 days.
Children with negative blood smears did not receive antimalar-
ials and were treated according to standard treatment algo-
rithms and the study physician’s judgment.
Sample size estimation. Sample size was based on episodes
of fever, and was estimated using a formula by Buderer for
diagnostic tests.18 Assuming a prevalence of malaria in the
study population of 50.5%,3 274 episodes of fever were
required to obtain sensitivity of 90% (precision of 5% and
alpha error of 0.05). To obtain a specificity of 90%, 280 epi-
sodes of fever were required. The higher sample size of 280
was used plus an additional 10% to allow for invalid or inac-
curate results to give a final sample size of 308 episodes of
fever. Febrile patients who fulfilled the inclusion criteria were
consecutively enrolled until the sample size was attained.
Recruitment of study participants. Children were screened
for enrollment into this RDT sub-study, according to the fol-
lowing eligibility criteria:1) age between 6 months and 5 years,
2) presence of fever (temperature ³ 38°C) or history of fever in
the previous 24 hours, 3) absence of World Health Organiza-
tion (WHO) symptoms and signs of severe malaria or danger
signs,2 4) willingness of parents/guardians to provide written
informed consent, 5) residence within 30 km of the clinic,
6) absence of another obvious cause of fever (as determined
by the study physicians), and 7) absence of non-falciparum
malaria species on blood smear. Eligible children who pre-
sented to the study clinic during the study period were con-
secutively enrolled until the target sample size of 308 fever
episodes was attained. Of this total, a convenience sample of
the first 140 fever episodes with microscopy confirmed
malaria, all of whom received antimalarial treatment accord-
ing to the TCC study protocol, were asked to participate in
the follow-up component of the study until Day 28 or until
development of a recurrent episode of microscopy confirmed
malaria. Follow-up study measurements were used to com-
pare duration of persistent antigenemia and to determine
RDT accuracy for malaria diagnosis in patients returning with
fever after efficacious malaria treatment.
Clinical and laboratory procedures. Demographic and clin-
ical information was obtained for patients who fulfilled the
inclusion criteria. Children who presented to the clinic with a
documented fever (tympanic temperature ³ 38.0°C) or his-
tory of fever in the previous 24 hours had blood obtained by
finger prick for a thick and thin blood smear and for RDTs.
The RDTs used were selected on the basis of performance in
the WHO Malaria RDT Product Testing Program (rounds 1–
3 results as available in 2011).9 They included CareStart
Malaria HRP2 Lot D21MO (September 2013) and CareStart
Malaria pLDH (P.f) Lot H11MY (July 2013) (Access Bio,
Inc., Somerset, NJ). Test kits were purchased directly from
the manufacturer and kept in their original packaging in the
study clinic at room temperature. The RDTs were prepared
and read according to manufacturer’s instructions by trained
laboratory technicians who were blinded to blood smear
results. Blood smears were stained with 2% Giemsa for
30 minutes and read by experienced laboratory technologists.
Thick smears were used to determine presence or absence of
Plasmodium parasites and gametocytes, and to calculate par-
asite density. Parasite densities were calculated by counting
the number of asexual parasites per 200 leukocytes (or per
500 leukocytes, if < 10 asexual parasites/200 leukocytes),
assuming a leukocyte count of 8,000/mL. A blood smear was
considered negative when the examination of 100 high-power
fields did not reveal asexual parasites. Thin smears were used
for confirmation of the parasite species. All blood slides were
read by microscopists with extensive experience in research
malaria microscopy. Quality control of microscopy was per-
formed as follows: all slides were reread by a second expert
microscopist and any discordance regarding presence or
absence of parasites was resolved by a third expert reading.
Microscopists were not aware of previous blood smear read-
ings or RDT results.
Diagnosis and treatment of malaria. If a child’s thick blood
smear was positive, s/he was diagnosed with malaria regard-
less of the parasite density and given directly observed ther-
apy with DP or AL according to the TCC trial protocol. If
the thick blood smear was negative, the patient was not
given antimalarial therapy and was managed at the discre-
tion of the study physicians. The RDT results were not
provided to treating clinicians, and were not used for treat-
ment decisions.
Follow-up of study participants. A convenience sample of
the first consecutive 140 smear-positive participants treated
for malaria were asked to return on Days 2, 7, 14, 21, and 28,
and any other day they felt ill during the 28-day follow-up
period. At each follow-up visit, history of fever and tympanic
temperature were recorded and blood was obtained by finger
prick for thick and thin blood smears and RDTs. Patients with
recurrent microscopy confirmed malaria during the 28 days
were discontinued from further follow-up.
Statistical analysis.Data were entered using EPI DATA 3.1
and analyzed using STATA version 12 (Stata, College Sta-
tion, TX). Comparison of characteristics of patients that were
and were not followed up were made using a t test for contin-
uous variables and c2 or Fisher’s exact test for categorical
variables. Sensitivity, specificity, positive predictive value
(PPV), and negative predictive value (NPV) of the RDTs
were estimated using expert microscopy results as the com-
parison standard. The percentage of false-positive RDT
results was defined as the percentage of RDT results that
remained positive during follow-up once the blood sample
became negative by microscopy. Comparisons of measures of
diagnostic accuracy were made using generalized estimating
equations with adjustment for repeated measures in the same
study participant. A P value of < 0.05 was considered statisti-
cally significant.
Ethical approval. The study protocol was approved by
Makerere University School of Medicine Research and Ethics
Committee and the Uganda National Council for Science and
Technology. Written informed consent was obtained from
participants’ parents or legal guardians at enrollment.
RESULTS
Study participants and baseline characteristics. The TCC
study participants presenting with 311 consecutive episodes
of fever were screened for this sub-study. Of these six were
excluded because of severe malaria (1), concomitant febrile
illnesses (4), and non-falciparum malaria (1); 305 fever
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episodes, recorded in 176 children, were evaluated. Study
participants’ median age was 52 months (interquartile range
[IQR] 50–55) and 53% were male (Table 1). Blood smears
were positive by expert microscopy for Plasmodium falciparum
in 202 (66%) fever episodes. A convenience sample of children
presenting with 140 consecutive smear-positive fever episodes
were followed up for 28 days (Figure 1). There were no differ-
ences in the demographic and clinical characteristics between
the 140 included and the 62 not included in the follow-up
component (Table 1).
Accuracy of HRP2 and pLDHRDTs for initial diagnosis of
malaria. For initial diagnosis of malaria, HRP2 had higher
sensitivity of 98% and NPV of 92% compared with pLDH
with sensitivity of 87% and NPV of 78% (P value < 0.001).
In contrast, pLDH had higher specificity of 96% and PPV of
98% compared with HRP2 with specificity of 54% and PPV
of 81% (Table 2).
Association of sensitivity of HRP2 and pLDH RDTs
with parasite density. The HRP2 result was negative in 60 of
305 initial episodes of fever and of these, 4 (7%) were false
negative when compared with expert microscopy. All the
false-negative HRP2 results were associated with a low para-
site density (32–112/mL).There were 124 negative pLDH
results of which 26 (21%) were false negative. Of the false-
negative pLDH results, 17 (65%) occurred at a parasite
density < 500/mL, 4 (15%) at parasite density between 500–
5,000/mL, 3 (12%) between 10,000 and 12,000/mL, and 2 (8%)
> 50,000/mL. We compared sensitivity of HRP2 and pLDH
at different parasite density categories. At parasite density
< 200/mL, pLDH sensitivity was 0% compared with 67% for
Table 1




BS positive patients that were
followed up, N = 131
BS positive patients that
were not followed up, N = 62
Median age in months (IQR) 52 (50–55) 53.3 (50.9–56.5) 54.4 (52.4–56.5)
Female, n (%) 144 (47) 75 (57) 30 (48)
Median weight in kg (IQR) 15.2 (13.9–16.5) 15.5 (14.0–16.9) 15.5 (14.1–17.2)
Median height in cm (IQR) 101 (98–104) 102 (98–104) 102.5 (98.8–105.0)
Median temperature °C (IQR) 37.3 (36.8–38.3) 37.5 (36.8–38.5) 37.9 (37.1–38.7)
Mean parasite density/mL (SD) 29204.6 (42498.3) 47130.4 (48984.9) 37530 (36674.1)
Patients with gametocytes, Day 0, n (%) 9 (3) 5 (4) 4 (6)
HIV-positive, n (%) 22 (7) 7 (5) 2 (3)
Drug use in the past one month
Antimalarial, n (%) 84 (28) 24 (18) 14 (23)
Cotrimoxazole prophylaxis, n (%) 22 (7) 7 (5) 2 (3)
BS = blood smear, IQR = interquartile range.
Figure 1. Study profile. Trial profile showing screened and enrolled patients, blood smear results, and those enrolled for follow-up. Of the
140 cases that were enrolled for follow-up, 131 were included in the final analysis.
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HRP2. At parasite density 200 to < 1,000 HRP2 sensitivity was
100%, whereas that of pLDH was sensitivity 60% (Figure 2).
Association of specificity of HRP2 and pLDH RDTs with
duration since last episode of malaria. The HRP2 result was
positive in 245 of 305 (80%) initial episodes of fever; of these,
46 (19%) were false positive when compared with expert
microscopy. Of the 46 false-positive HRP2 results, 29 (63%)
occurred in children who had a documented malaria episode
in the previous 4 weeks and 43 (93%) occurred in children
who had a documented malaria episode in the previous
8 weeks. For the same 305 fever episodes, there were
181 (59%) positive pLDH tests of which 4 (2%) were false
positive when compared with expert microscopy. All the false-
positive pLDH tests occurred in children who had a docu-
mented malaria episode in the previous 5 weeks. We stratified
duration since the last documented episode of malaria into
four groups. For patients who had had a malaria episode in
the previous 2 weeks, HRP2 had a very low specificity of 11%
compared with 94% for pLDH. Specificity of HRP2 was 89%
for patients who had had a malaria episode within the previ-
ous 10 weeks compared with 100% for pLDH (Figure 3).
Persistence of HRP2 and pLDH antigenemia during
follow-up.Among the 140 malaria episodes that were followed
up, 131 were included in the final analysis (Figure 1). Of the
131, 52 (40%) had recurrent peripheral parasitemia during
follow-up and were not included in the analysis of duration of
persistent antigenemia. There were 94% false-positive HRP2
test results on Day 2 and 51% false-positive test results on
Day 28. On Day 2, pLDH had 5% false-positive results and
no false-positive result on Day 14, 21, and 28 (Figure 4).
Association of pretreatment parasite density with duration
of antigenemia. Pretreatment parasite density was found to
predict the duration of persistent antigenemia of the HRP2-
based RDT. We stratified parasite density into four groups
and compared the percentage of false-positive HRP2 results
on each day of follow-up with pretreatment parasite density.
Among patients with the highest parasite density > 100,000,
89% had false-positive HRP2 results on Day 28 compared
with 4% of those with parasite density < 10,000 (Figure 5).
Accuracy of HRP2 and pLDH RDTs for diagnosis of
malaria in children with recurrent fever after treatment of
uncomplicated malaria. There were 59 episodes of recurrent
fever after completion of antimalarial treatment. Of these,
46 (78%) occurred after Day 14 of follow-up. Of the 59 epi-
sodes of recurrent fever, 32 (54%) were blood smear positive
for Plasmodium falciparum and these all occurred after Day 17
of follow-up. For diagnosis of malaria in children with recurrent
fever after treatment, HRP2 had higher sensitivity of 100%
and NPV of 100% compared with pLDH with sensitivity of
91% and NPV of 90%. In contrast, pLDH had higher speci-
ficity of 100% and PPV of 100% compared with HRP2 with
specificity of 33% and PPV of 64% (Table 3). There were
50 positive HRP2 results of which 18 (36%) were false posi-
tive. All of the 18 false-positive results occurred in children
who had had a documented malaria episode and used an
antimalarial in the previous 1 month. Of the 18 children,
17 (94%) had a malaria episode in the previous 21 days. There
was no false-positive pLDH result among the 29 positive
pLDH results obtained. There was no false-negative HRP2
result among the 9 negative HRP2 results. There were 30 neg-
ative pLDH results of which 3 (10%) were false negative. All
the false-negative pLDH results were associated with rela-
tively low parasite densities of 80/mL, 400/mL, and 520/mL.
DISCUSSION
For initial diagnosis of malaria in this high transmission
area, as expected the HRP2-based malaria RDT showed a
Table 2
Accuracy of HRP2- and pLDH-based malaria rapid diagnostic tests (RDTs) for initial diagnosis of malaria in 305 children using expert
microscopy as a gold standard
Accuracy HRP2 RDT pLDH RDT P value
Sensitivity (%) (95% CI) 98 (94–99) 87 (81–91) < 0.001
Specificity (%) (95% CI) 54 (45–64) 96 (90–98) < 0.001
Positive predictive value (%) (95% CI) 81 (76–86) 98 (94–99) < 0.001
Negative predictive value (%) (95% CI) 92 (82–96) 78 (70–85) < 0.001
HRP2 = histidine-rich protein 2; pLDH = Plasmodium lactate dehydrogenase; CI = confidence interval.
Figure 2. Relationship between parasite density and sensitivity of
histidine-rich protein 2 (HRP2) and Plasmodium lactate dehydroge-
nase (pLDH) rapid diagnostic tests (RDTs). At parasite densities
< 1,000/mL, the sensitivity of pLDH is very low compared with HRP2.
Figure 3. Relationship between specificity of histidine-rich pro-
tein 2 (HRP2) and Plasmodium lactate dehydrogenase (pLDH),and
time since last malaria episode. The pLDH had acceptable specificity
when used in patients with a recent malaria episode, unlike HRP2,
which showed poorer specificity.
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higher sensitivity and NPV compared with pLDH, whereas
the pLDH assay showed a higher specificity and PPV. The
lower sensitivity and NPV of pLDH could be attributed
mainly to its declining ability to detect antigen at lower para-
site densities. Although highly sensitive for initial diagnosis of
malaria, the HRP2-based RDT had low specificity because of
a large number of false-positive results, most of which were
obtained in patients who had received treatment of micros-
copy confirmed malaria in the previous 1 month. This implies
that persistent antigenemia of HRP2 in these patients con-
tributed to the low specificity of the HRP2- based RDT, as
suggested by previous studies.10,11 Another factor that con-
tributes to false-positive HRP2 results is sub-patent para-
sitemia, i.e., presence of parasite density levels below the
detection threshold for expert microscopy of 10–50 parasites/
mL.8,19 A study done at sites of varying malaria transmission
intensity in Uganda found up to 45% of samples that were
negative for malaria by microscopy to be positive by PCR at
the site with the highest transmission rate.8 The high sensitiv-
ity and NPV of the HRP2-based RDT implies that true
malaria cases would rarely be missed making it an appropriate
test for initial diagnosis of malaria. However, the high number
of false-positive HRP2 results and low specificity could lead
to over-diagnosis of malaria in patients presenting with alter-
native causes of fever. These results imply that when a posi-
tive HRP2 result is obtained in a patient with history of recent
malaria treatment, clinicians should look for alternative
causes of fever to improve patient management and prevent
misuse of ACTs.
The pLDH-based malaria RDT showed rapid clearance of
antigenemia after treatment of uncomplicated malaria com-
pared with the HRP2-based RDT. Persistent antigenemia of
HRP2 has been shown for up to 28–42 days after successful
treatment and clearance of malaria parasites in peripheral
blood.10,11,13 Although the mechanism of HRP2 clearance is
not well understood, some features that appear to be associ-
ated with its persistence after efficacious treatment include
high pretreatment parasite density, presence of subpatent
parasitemia, and presence of gametocytes, which continue to
secrete antigen. In this study, children with a higher pretreat-
ment parasite density had longer duration of persistent HRP2
antigenemia. Some studies have identified presence of antigen-
secreting gametocytes as another possible cause of persis-
tent HRP2 or pLDH antigenemia.20 However, gametocytes
were not found to significantly affect duration of antigenemia
in other assessments.10,11 In this study the gametocyte rate of
4% in patients who were followed up was too low to identify
a significant correlation with the duration of antigenemia.
Other studies using molecular methods to identify gameto-
cytes have suggested that microscopy dramatically underesti-
mates gametocytemia.21 Thus, some of the HRP2 positives
might be explained by subpatent gametocytemia, in addition
to persistence of antigen from recently cleared blood-stage
parasites. In addition, in a large surveillance project that
included patients of all ages, patient age was also found to
affect false-positive HRP2 results. Abeku and others22 found
false-positive rates of HRP2-based RDT to decline in older
age groups; the authors suggest this may be a result of
acquired immunity in clearing parasite antigens. In a clinical
setting, persistent antigenemia detectable by HRP2-based
RDTs limits their use in monitoring treatment of malaria.
This study conducted in a high transmission setting confirms
that a positive HRP2 result obtained within 28 days of anti-
malarial treatment has low specificity and may lead to over-
diagnosis of malaria. The pLDH-based RDT however showed
higher specificity soon after treatment and may be more use-
ful in monitoring response to antimalarial treatment.
The pLDH-based RDT showed acceptable sensitivity and
specificity for diagnosis of malaria in children with recurrent
episodes of fever after administration of ACT for uncompli-
cated malaria. Positive predictive value of HRP2 for initial
diagnosis of malaria was relatively low at 81% and even lower
at 64% for diagnosis of malaria in children with recurrent
episodes of fever within 28 days of efficacious treatment. This
is of concern particularly in high transmission areas that still
exist across much of East and Central Africa, where in the
setting of frequent prolonged antigenemia, even with RDT
use fever may be over-diagnosed as malaria as a result of
the detection of antigen from previous infections, leading to
Figure 4. Duration of antigenemia detected by histidine-rich pro-
tein 2 (HRP2) and Plasmodium lactate dehydrogenase (pLDH)-
based rapid diagnostic tests (RDTs) during follow-up. The figure
shows duration of antigenemia of HRP2 and pLDH during follow-up
represented by percentage of false-positive HRP2 and pLDH RDTs,
as compared with expert microscopy, obtained on each day of follow-
up in 79 children without recurrent parasitemia. There was no false-
positive pLDH result after Day 7, although 51% of HRP2 results
were false positive on Day 28.
Figure 5. Proportion of children with continued false-positive
histidine-rich protein 2 (HRP2) results during follow-up, stratified by
Day 0 parasite density. The figure shows the proportion of children
with false-positive HRP2 results on each day of follow-up, stratified
into four groups of pretreatment parasite density, in 79 children with-
out recurrent parasitemia during follow-up. Children with initial par-
asite density £ 10,000 had a smaller proportion of false-positive results
on each day of follow-up when compared with those with parasite
density > 100,000.
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misuse of antimalarials and failure to identify and treat alter-
native fever etiologies in these patients.
Significantly, a majority of the false-positive HRP2 tests
occurred in children who had been diagnosed and treated for
malaria in the previous 21 days, implying that an HRP2 test
result obtained within 3 weeks of antimalarial treatment has a
high likelihood of being false positive. These results suggest
that for fever management in high transmission areas, HRP2-
based tests are of limited use within a minimum of 3 weeks
following a malaria episode. On the other hand, the pLDH-
based RDT showed excellent specificity and positive predic-
tive value and could be recommended for evaluation of
patients who return with fever after completion of treatment
of an initial malaria episode. The potential for false-negative
pLDH results, although mostly occurring in cases of low par-
asite density, remains a point of caution, and repeat evalua-
tion for persistent symptoms is warranted.
To our knowledge, there is only one previous, small assess-
ment of HRP2 and pLDH RDT accuracy for malaria diag-
nosis in a higher transmission zone after completion of
efficacious antimalarial treatment. A study of 53 children by
Aydin-Schmidt and others,23 in a “moderately high” transmis-
sion area in Tanzania, found that the HRP2-based RDT
detected only two of 10 recurrent infections because of persis-
tent positivity up to the day of recurrent infection, whereas
the pLDH-based RDT was able to detect eight of the 10.
This study used expert microscopy, and not a more sensi-
tive nucleic acid-based assay, as a gold standard. The use of a
gold standard with relatively low sensitivity likely contributed
to the low specificity of the HRP2-based RDT, as some
results classified as false positives would have been true posi-
tives with a more sensitive gold standard. Nonetheless, the
majority of false-positive HRP2-based results were in chil-
dren recently treated for malaria, suggesting that the main
limitation to specificity was the ability of the HRP2-based
assay to identify antigen well after clearance of parasites.
Furthermore, the Uganda National Malaria Control Program
policy currently recommends confirmation of malaria infec-
tion with microscopy or RDT, and it is not clear that more
sensitive assays for diagnosis would be helpful clinically,
therefore considering results based on the microscopy gold
standard is most relevant for current malaria control policy.
In addition to accuracy, other factors such as economic
considerations play a role in decisions about RDT implemen-
tation. The cost effectiveness of using RDTs, compared with
microscopy or presumptive treatment of malaria, varies
across different patient populations and malaria prevalences,
and is also affected by prescribers’ response to RDT results.
For example, in high transmission areas, some studies have
found RDTs to be cost-effective compared with microscopy
and presumptive treatment of malaria.24 However, among
children < 5 years of age in high transmission settings, some
investigators suggest that presumptive treatment of malaria
may be more cost effective than RDTs given the high preva-
lence of malaria in this age group.25 Economic factors may be
weighed alongside other potential benefits of RDT use in
decision-making for given regions.
In this highly endemic setting, HRP2-based RDTs should
be used for initial diagnosis of malaria; however, in patients
who have had a malaria episode in the previous 3 weeks,
pLDH-based RDTs appear to be more useful for monitoring
response to treatment and diagnosis of new episodes of
malaria after treatment. However, a recommendation to use
two different RDTs for two different indications may be very
challenging to implement in routine clinical practice. At least,
where HRP2-based RDTs are used, clinicians should be
trained to search for an alternative diagnosis in patients pre-
senting with fever following a recent malaria episode.
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